Eisai subsidiary names Antonio Gualberto as CMO

20 February 2020

H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai (TYO: 4523), has named industry veteran Antonio Gualberto its chief medical officer (CMO).

Dr Gualberto’s most recent role was as co-founder and CMO at Californian company Kura Oncology (Nasdaq: KURA), where he led the discovery of the mechanism of action and clinical proof-of-concept of farnesyl transferase inhibitors as well as bringing a pipeline of new agents to the clinic.

Prior to this, Dr Gualberto held positions of increasing responsibility at EMD Serono, a subsidiary of Merck KGaA (MRK: DE), Takeda (TYO: 4502) and Pfizer (NYSE: PFE).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK